Fig. 3From: Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitorsReason for pseudoprogression. TL target lesion, NTL non-target lesion, New TL new target lesion, New NTL new non-target lesion, multiple combination of reasonsBack to article page